Daclizumab en la esclerosis múltiple

Published: Jan 1, 2018
Abstract
Daclizumab is a monoclonal antibody directed against the CD25 subunit of the interleukin-2 receptor, investigated as a disease-modifying therapy in relapsing-remitting multiple sclerosis. The present review addresses how the drug was developed, the known mechanism of action of the drug and the up-to-date data of efficacy and safety.Daclizumab has shown superiority in prevention of relapses against placebo and low-dose interferon beta-1a at a...
Paper Details
Title
Daclizumab en la esclerosis múltiple
Published Date
Jan 1, 2018
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.